Valproamide suppository

1 Pharmacology: This product is a broad-spectrum anticonvulsant drug of the valproic acid class. Its mechanism of action has not yet been elucidated. It may be through the inhibition of the γ-aminobutyric acid (GABA) degradation enzyme system in the brain to varying degrees, thereby increasing the concentration of GABA in the brain, while increasing the activity of glutamate dehydrogenase, thereby increasing the synthesis of GABA in the brain. On the other hand, preventing the reuptake of GABA by axons and glial cells can also increase the concentration of GABA in the synaptic cleft. Increase the postsynaptic inhibition achieved by GABA. Studies have shown that it can prevent the spread of abnormal discharges in epileptic lesions. 2 Toxicological animal experiments have shown that this product has no irritating effect on the rectal mucosa of rabbits administered rectal; experimental results and pathological examinations have shown that rabbits and dogs given large doses of valproic acid orally have no irritating effect on the rectal mucosa of rabbits.

The main ingredient of this product is valproamide, and its chemical name is dipropylacetamide.

This product is a milky white suppository.

Used to prevent and treat various types of epilepsy. Suitable for epileptic tonic-clonic seizures, absence seizures, infantile spasms, etc.

Rectal administration. 8~18mg/kg per day, twice a day or as directed by a doctor. Children under 2 years old: 100mg per day, twice a day; children aged 2-7 years old: 200mg per day, twice a day; children aged 7-15 years old: 400mg per day, twice a day; adults aged 16 years old or older: 600mg per day, twice a day.

During the use of this product, a small number of patients may experience changes in appetite, nausea and vomiting, headache, dizziness, fatigue and drowsiness, which will disappear on their own after stopping the drug.

Contraindicated in patients with liver disease or significant liver impairment.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. This product can pass through the placental barrier. There are reports of teratogenicity in animal experiments, which have not yet been confirmed in humans, but pregnant women should use it with caution. 2. Valproic acid can be secreted into breast milk through the mammary glands, with a concentration of 1% to 10% of the maternal blood drug concentration. Breastfeeding women should use it with caution. Precautions for the elderly: Not yet clear.

1 This product is used in combination with general anesthetics or central nervous system depressants, the clinical effect of the latter may be more obvious. 2 When used in combination with anticoagulants such as warfarin or heparin, and thrombolytic drugs, the risk of bleeding increases. 3 When used in combination with aspirin or dipyridamole, it can prolong bleeding time due to reduced platelet aggregation. 4 When used in combination with phenytoin sodium and phenobarbital, the blood concentrations of phenytoin sodium and phenobarbital will increase. 5 When used in combination with primidone, it can also cause an increase in blood concentrations and lead to poisoning. If necessary, the dosage of primidone needs to be reduced. 6 When used in combination with clonazepam to prevent and treat absence seizures, there have been reports of a few cases where it induced absence seizures.

Keep in a dark place and sealed at a temperature below 30℃.

0.6g

24 months